# GNA13

Source: https://onco.cc/targets/gna13/  
OnCo record `gna13` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GNA13 (Guanine nucleotide-binding protein subunit alpha-13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and 1 more.

## Summary

Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signalling systems. Activates effector molecule RhoA by binding and activating RhoGEFs (ARHGEF1/p115RhoGEF, ARHGEF11/PDZ-RhoGEF and ARHGEF12/LARG). GNA13-dependent Rho signalling subsequently regulates transcription factor AP-1 (activating protein-1).

CIViC holds 3 clinical evidence items and 0 assertions across 1 variant. IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Bladder Urothelial Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: G protein subunit alpha 13; Guanine nucleotide-binding protein subunit alpha-13; G13; MGC46138
- Tags: cancer-genes-wave
- Symbol: GNA13
- Class: tumor-suppressor
- Biology: Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signalling systems. Activates effector molecule RhoA by binding and activating RhoGEFs (ARHGEF1/p115RhoGEF, ARHGEF11/PDZ-RhoGEF and ARHGEF12/LARG). GNA13-dependent Rho signalling subsequently regulates transcription factor AP-1 (activating protein-1). Promotes tumour cell invasion and metastasis by activating RhoA/ROCK signalling pathway. Inhibits CDH1-mediated cell adhesion in a process independent from Rho activation. In lymphoid follicles, transmits P2RY8- and S1PR2-dependent signals that lead to inhibition of germinal centre (GC) B cell growth and migration outside the GC niche. Location: Cell membrane; Melanosome; Cytoplasm; Nucleus (UniProt). Locus 17q24.1 (HGNC).
- Where found: Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA); Non-Hodgkin lymphoma: IntOGen driver in 1 cohort (MLYM); Diffuse large B-cell lymphoma: CIViC evidence names this disease; IntOGen driver in 1 cohort (DLBCLNOS); Burkitt lymphoma: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 3 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:4381: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4381
- UniProt Q14344: https://www.uniprot.org/uniprotkb/Q14344/entry
- NCBI Gene 10672: https://www.ncbi.nlm.nih.gov/gene/10672
- Ensembl ENSG00000120063: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120063

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Burkitt lymphoma](https://onco.cc/cancers/burkitt-lymphoma/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/gna13.json